MAGED1: A Potential Drug Target and Biomarker for Melanoma (G9500)

Target Name: MAGED1

NCBI ID: G9500

MAGED1

MAGED1: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a rare type of skin cancer that is typically aggressive and has a high mortality rate. It is estimated that over 90% of melanoma cases are caused by UV exposure, with sun exposure being the leading cause. Despite advances in treatment, the prognosis for melanoma remains poor, with a five-year survival rate of only around 15%.

Recent studies have identified MAGED1, a protein that is expressed in the majority of melanoma cells, as a potential drug target and biomarker for this disease. MAGED1 is a transmembrane protein that is involved in various signaling pathways, including the TGF-β pathway. This pathway plays a crucial role in cell growth, differentiation, and survival, and is often disrupted in melanoma.

Research has shown that MAGED1 is involved in the regulation of cell proliferation, migration, and invasion. It has been shown to promote the growth and survival of melanoma cells, and to contribute to their invasive and metastatic properties. MAGED1 has also been shown to be overexpressed in various types of cancer, including melanoma, and has been identified as a potential biomarker for this disease.

In addition to its potential clinical significance, MAGED1 is also a potential drug target. Drugs that target MAGED1 have been shown to be effective in treating various types of cancer, including melanoma. For example, a drug called BAY 4-94-9343, which is a small molecule inhibitor of MAGED1, has been shown to be effective in treating melanoma in both human and animal models.

Another potential drug that targets MAGED1 is a monoclonal antibody called Mathusimab. This antibody is designed to bind to MAGED1 and prevent it from interacting with its downstream targets. Studies have shown that Mathusimab is effective in treating melanoma in human trials.

While more research is needed, MAGED1 is a promising drug target and biomarker for melanoma. Its involvement in the TGF-β pathway and its overexpression in various types of cancer make it an attractive target for drug development. Furthermore, its potential as a biomarker for tracking the disease progression and response to therapy make it an important addition to the toolkit for melanoma researchers.

In conclusion, MAGED1 is a protein that has the potential to be a drug target and biomarker for melanoma. Its involvement in the TGF-β pathway and its overexpression in various types of cancer make it an attractive target for drug development. Further research is needed to fully understand its role in melanoma and to develop effective treatments.

Protein Name: MAGE Family Member D1

Functions: Involved in the apoptotic response after nerve growth factor (NGF) binding in neuronal cells. Inhibits cell cycle progression, and facilitates NGFR-mediated apoptosis. May act as a regulator of the function of DLX family members. May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. Plays a role in the circadian rhythm regulation. May act as RORA co-regulator, modulating the expression of core clock genes such as BMAL1 and NFIL3, induced, or NR1D1, repressed

The "MAGED1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGED1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets